Pacer Advisors Inc. Makes New Investment in GoodRx Holdings, Inc. $GDRX

Pacer Advisors Inc. purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 871,520 shares of the company’s stock, valued at approximately $3,687,000. Pacer Advisors Inc. owned about 0.25% of GoodRx at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Osaic Holdings Inc. raised its position in GoodRx by 221.2% in the 2nd quarter. Osaic Holdings Inc. now owns 23,713 shares of the company’s stock worth $118,000 after buying an additional 16,330 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of GoodRx by 155.7% in the second quarter. Headlands Technologies LLC now owns 37,914 shares of the company’s stock worth $189,000 after acquiring an additional 23,084 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after purchasing an additional 7,580 shares during the last quarter. Sugar Maple Asset Management LLC bought a new position in GoodRx during the second quarter valued at approximately $189,000. Finally, State of Tennessee Department of Treasury purchased a new stake in GoodRx in the second quarter worth approximately $145,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GDRX. Mizuho decreased their target price on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Barclays began coverage on GoodRx in a report on Monday, December 8th. They issued an “underweight” rating and a $3.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen downgraded GoodRx from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, TD Cowen lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, GoodRx presently has an average rating of “Hold” and an average target price of $5.15.

GoodRx Price Performance

NASDAQ GDRX opened at $2.69 on Tuesday. The business’s fifty day moving average is $3.00 and its 200 day moving average is $3.92. GoodRx Holdings, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. The company has a market capitalization of $913.07 million, a PE ratio of 29.89, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. During the same period last year, the business earned $0.08 EPS. The firm’s quarterly revenue was up .4% compared to the same quarter last year. Sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.17% of the stock is owned by corporate insiders.

GoodRx Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.